CJC-1295: turning your own growth hormone back up

Growth hormone is the signal behind how you recover, how you sleep, how easily you hold muscle and shed fat. Your body fires it in sharp bursts, mostly at night. In your twenties those bursts run strong. Then, year by year, they fade.

CJC-1295 is a piece of engineering built to turn them back up — a single shot that tells your own pituitary to keep releasing its own growth hormone, not for minutes, but for days. And here’s what sets it apart from almost everything else on the longevity menu: someone actually ran the human trial. It worked. The hormones went up and stayed up, exactly the way the chemistry promised.

The promise: your own growth hormone, turned back up

Start with what makes this exciting, because it genuinely is.

CJC-1295 doesn’t hand you growth hormone from a bottle. It leans on the gland that already makes it and asks for more — sustained, on your body’s own schedule. In the one human trial that exists, a single dose lifted growth hormone two to ten times above baseline for the better part of a week, and IGF-1 — the long-acting growth signal that GH switches on — stayed up for nine to eleven days. Dose again weekly and IGF-1 rode above baseline for close to a month.

Growth hormone and IGF-1 sit behind the exact things men come to this for: faster recovery between hard sessions, deeper sleep, an easier time holding lean mass and dropping fat, tissue that repairs the way it did a decade ago. Raise them — sustainably, from your body’s own supply — and that is the whole promise. At the level of hormone biology, CJC-1295 delivers it.

The clever bit: one shot, days of signal

The reason it lasts is a nice piece of chemistry, and it earns a plain-language minute.

The natural messenger CJC-1295 imitates lasts only minutes in your blood before enzymes chew it up. The team at ConjuChem that built and named CJC-1295 in 2005 fixed that two ways: they swapped a few of its building blocks so the enzymes can’t grip it, then bolted on a chemical handle that latches onto albumin, the most common protein in your bloodstream. Albumin hangs around for about three weeks. Riding on its back, CJC-1295 turns minutes of signal into days.

The obvious worry with a signal that long is that it would flatten your natural rhythm — turn those sharp nightly pulses into a flat hum. A second 2006 study went looking for exactly that and found the pulses held. The peptide kept the gland working without erasing the beat it normally fires on. That is the design doing precisely what it was meant to.

How far the proof actually goes

The excitement only counts if the boundary around it is drawn straight, so here it is.

That 2006 human trial is a good one — randomised, placebo-controlled, no serious side effects at the doses tested. But it measured hormones. It watched growth hormone and IGF-1 climb and stay high. It did not measure muscle. It did not measure body fat, sleep, recovery, or a single one of the outcomes the marketing sells. The step from your hormones rose to your body changed is the step nobody has yet run the trial to prove — not in CJC-1295, not so far.

The nearest thing to outcome evidence is a 2026 review reporting that CJC-1295 paired with ipamorelin improved muscle force in mice bred to lose it — and the same review says plainly that no human data on that combination exists. A 2026 aging review lands in the same place for the whole growth-hormone-peptide class: the mechanism is real, the right dose isn’t agreed, and there’s no validated way yet to measure whether it’s working in you.

There’s a longer-range unknown too. The human study dosed people for weeks. Men who use CJC-1295 for anti-aging often stay on it for years, keeping IGF-1 elevated the whole time — and no one has followed those men to see what chronically raised IGF-1 does over the long haul. That isn’t a red flag. It’s an open question, and honesty means naming it as one.

One name, two very different compounds

This is the part that trips up nearly everyone buying grey-market, so it’s worth stopping on.

CJC-1295 names two different molecules. The one in the 2006 trial — the one carrying that albumin handle, written CJC-1295 with DAC — is the long-acting version: days of effect from a single shot. The one often sold under the bare name CJC-1295, and more honestly called MOD-GRF(1-29), has no albumin handle at all. Its half-life is about thirty minutes, and it needs dosing several times a day to do anything.

Same name. Completely different pharmacology. When someone points at that clean 2006 human data to sell you CJC-1295, the fair question is which molecule they studied and which one is going in the vial. From a research-chemical site, you have no way to know.

What the FDA already decided

Here’s where the story turns sharper than the forums admit. CJC-1295 isn’t on the FDA’s 2026 or 2027 compounding review lists — but not because it slipped through unnoticed. The review already happened. In December 2024 the FDA’s compounding advisory committee looked at CJC-1295 and voted against adding it to the list of substances pharmacies are cleared to compound. What that vote means for future legal access — and what the committee can and can’t actually decide — is the subject of what a PCAC review actually is. The short version: the question got asked, and for now the answer was no. It has never held FDA approval for any use either — no approved drug application, no label.

For anyone drug-tested, the line is simple. Growth-hormone-releasing peptides sit on the WADA prohibited list, banned in and out of competition, and CJC-1295 falls squarely inside that class. Not named specifically is not a loophole.

The version worth waiting for

So here is the honest shape of CJC-1295 in 2026. A real human trial, which almost nothing on this menu can claim. A mechanism that does exactly what it says at the hormone level. A genuine gap between raised hormones and the life outcomes people are chasing. And two compounds wearing one name, sold by people who mostly can’t tell you which is which.

Every one of those is a supply problem, not a science problem. The version worth being excited about knows which molecule is in the vial, comes from a physician who understands the difference between the two forms, and is tested batch by batch before it reaches you. Wolverine Health is being built to be that version — for the day the law makes room for it. Add your name below and we’ll tell you the moment it opens.